230 likes | 350 Vues
This presentation outlines a strategic shift towards performance management in clinical research, detailing the integration of portfolio data and RTT data through the MH delivery team. It highlights the need for autonomy in practice while implementing supportive measures for high performers and addressing risk management for underperformers. Notably, it reviews clinical claims data from 1995 to 2010, demonstrating the minimal impact of clinical trials on the overall claims against the NHS, thereby reinforcing the importance of continued investment and focus on research governance and risk management in clinical trials.
E N D
Ever Decreasing Circles David G Smithard MD FRCP RICR Clinical Director Kent and Medway CLRN
Recruitment to Time and Target – based on portfolio data combined with portal RTT data collected by MH delivery team
CLRN • Support for • Portfolio Dr Ian Akers • Industry James Porecca • Research Governance • Hazel Crawford • Delivery Team • MHRN • DeNDRoN
Set-up phase is over! Shift towards performance management • Management through the Coordinating Centres/Teams • “With performance comes autonomy” – light touch for those who deliver • “Special measures” for those who don’t
Risk Management • • There were 57,065 clinical claims through the NHS Litigation • Authority between 1995 and 2010 • • Of these, just 6 related to clinical trials (0.01% of total) • • Of the six claims recorded, 3 were rejected, one is ongoing and two • received payment. • • The total amount paid in damages for clinical claims (minus those • related to trials) between 1995 and 2010 was £8,660,644,000 • • The total amount paid out in damages for claims relating to clinical • trials was £235,000 (£160,000 + costs). This is just 0.002% of the • total damages figure. • • Networks are spending 8% of Budget on RMG